NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
07/01/2020
Voltar para busca
Dado oficial do USPTO
NASALCARE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
48
Atualização mais recente
07/01/2020
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5
Data de depósito
22/06/2008
Data de registro
29/09/2009
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
07/01/2020
Última transação
07/01/2020
Escritório responsável
United States Patent and Trademark Office
Código da situação
800
Cadastro oficial
Principal Register
Primeiro uso
02/01/2007
Primeiro uso no comércio
02/01/2007
Código do desenho
3
Tipo de titular
03
Localização do titular
Newport, DE
Examinador
BENJAMIN, SARA NICOLE
Unidade examinadora
M10
Localização atual
GENERIC WEB UPDATE
Descrição da marca
The mark consists of the wording "NASALCARE" with two curved lines representing air or vapor emanating from the "L".
Titulares e representantes
Titulares
TechWorld Corporation, Inc.
TechWorld Corporation, Inc.
Representantes
Lilly Zhang TechWorld Corporation, Inc.
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Analgesic and muscle relaxant pharmaceutical preparations; Anti-diabetic pharmaceuticals; Antibacterial pharmaceuticals; Antimicrobial preparations for inhibiting microbiological decomposition in foodbeveragesanimal feed and pharmaceuticals; Antimicrobial preservatives for cosmetics and pharmaceuticals; Astringents; Bismuth preparations for pharmaceutical purposes; Cardiovascular pharmaceuticals; Dermatological pharmaceutical products; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of a coating for macromolecule agents that facilitate the delivery of a wide range of pharmaceuticals; Gelatin capsules sold empty for pharmaceuticals; Homeopathic pharmaceuticals for use in the treatment of allergy and respiratory tract infections; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Inhalers filled with anti-infectives and anti-allergy pharmaceuticals; Injectable pharmaceuticals for treatment of anaphylactic reactions; Intravenous fluids used for rehydrationnutrition and the delivery of pharmaceutical preparations; Ocular pharmaceuticals; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseasesblood disorderspaininflammationsepsisalopeciaobesity and cognitive disorders ; Pharmaceutical preparations and substances for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous systemthe immune systemthe cardio-vascular systemthe metabolic systemthe respiratory systemthe musculo-skeletal systemthe genitourinary system; for the treatment of inflammatory disorders; for use in dermatologyoncologyhematology and in tissue and organ transplantationin ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseasesfor the treatment of bacteria-based diseasesfor the treatment of diabetesanti-infective preparationsantiviral preparationsantibioticsantifungal preparations and vaccines ; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparationsantidepressants; Pharmaceutical preparationsappetite suppressants; Pharmaceutical preparationsa blood clotting aid and delivery system for use in human and veterinary medicine; Pharmaceutical preparationsa drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparationsanticoagulants; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseasesfor the treatment of cancer; Pharmaceutical solutions used in dialysis; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticalsanti-infectives; Pharmaceuticalsantihelmintics; Pharmaceuticalsinducers of erections; Pharmaceuticalslipid lowering agents; Plant extracts for medicalveterinary and pharmaceutical purposes; Potassium preparations for pharmaceutical purposes; Radioactive pharmaceutical preparations for use in vivo diagnostic or therapeutic use; Synthetic peptides for pharmaceutical purposes; Unit dose capsules sold empty for pharmaceutical use; Vitamin and mineral preparations for use as ingredients in the food and pharmaceutical industry; Yeast or yeast extracts for medicalveterinary or pharmaceutical purposes
Publicações
Histórico de despachos e eventos da marca no USPTO.
48 publicações encontradas
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
07/01/2020
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
07/01/2020
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
06/01/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/01/2020
PR89
POST REGISTRATION ACTION MAILED - SEC. 8 & 9
07/07/2019
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
07/07/2019
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
21/06/2019
E89R
TEAS SECTION 8 & 9 RECEIVED
21/06/2019
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
29/09/2018
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
12/10/2016
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
12/10/2016
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
28/09/2016
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
27/09/2016
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/06/2016
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
27/05/2016
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
08/04/2016
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/04/2016
PR23
POST REGISTRATION ACTION MAILED - SEC. 8 & 15
28/03/2016
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
25/03/2016
E815
TEAS SECTION 8 & 15 RECEIVED
25/03/2016
PR23
POST REGISTRATION ACTION MAILED - SEC. 8 & 15
13/12/2014
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
24/11/2014
PR23
POST REGISTRATION ACTION MAILED - SEC. 8 & 15
06/10/2014
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
06/10/2014
E815
TEAS SECTION 8 & 15 RECEIVED
30/09/2014
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
30/09/2014
R.PR
REGISTERED-PRINCIPAL REGISTER
29/09/2009
TMBN
TTAB RELEASE CASE TO TRADEMARKS
26/08/2009
OP.T
OPPOSITION TERMINATED NO. 999999
26/08/2009
OP.D
OPPOSITION DISMISSED NO. 999999
26/08/2009
OP.I
OPPOSITION INSTITUTED NO. 999999
12/03/2009
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
04/02/2009
PUBO
PUBLISHED FOR OPPOSITION
20/01/2009
NPUB
NOTICE OF PUBLICATION
31/12/2008
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
16/12/2008
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
16/12/2008
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
16/12/2008
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
16/12/2008
ALIE
ASSIGNED TO LIE
16/12/2008
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
01/12/2008
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/12/2008
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/10/2008
GNRT
NON-FINAL ACTION E-MAILED
03/10/2008
CNRT
NON-FINAL ACTION WRITTEN
03/10/2008
DOCK
ASSIGNED TO EXAMINER
26/09/2008
MDSM
NOTICE OF DESIGN SEARCH CODE MAILED
26/06/2008
NWAP
NEW APPLICATION ENTERED
25/06/2008
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace NASALCARE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.